Insulin glargine is more potent in activating the human IGF-I receptor than human insulin and insulin detemir

Growth Hormone and IGF Research

Volumn 20, Issue 6, 2010, Pages 427-431

  Varewijck, A J ^a   Goudzwaard, J A ^a   Brugts, M P ^a   Lamberts, S W J ^a   Hofland, L J ^a   Janssen, J A M J L ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

IGF I receptor; Insulin analogues; Insulin receptor

Indexed keywords

INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; INSULIN RECEPTOR; INSULIN RECEPTOR A; INSULIN RECEPTOR B; NEUTRAL INSULIN; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHOSPHORYLATION; BIOASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG USE; EMBRYO; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN DETERMINATION;

ANTIGENS, CD; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME ASSAYS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; OSMOLAR CONCENTRATION; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN;

EID: 78649633536     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2010.10.002     Document Type: Article

References (29)

1. Seino S., Seino M., Nishi S., Bell G.I. Structure of the human insulin receptor gene and characterization of its promoter. Proc. Natl Acad. Sci. USA 1989, 86:114-118.
2. Mosthaf L., Grako K., Dull T.J., Coussens L., Ullrich A., McClain D.A. Functionally distinct insulin receptors generated by tissue-specific alternative splicing. EMBO J. 1990, 9:2409-2413.
3. Benecke H., Flier J.S., Moller D.E. Alternatively spliced variants of the insulin receptor protein. Expression in normal and diabetic human tissues. J. Clin. Invest. 1992, 89:2066-2070.
4. Belfiore A., Frasca F., Pandini G., Sciacca L., Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr. Rev. 2009, 30:586-623.
5. Yarden Y., Ullrich A. Growth factor receptor tyrosine kinases. Annu. Rev. Biochem. 1988, 57:443-478.
6. LeRoith D., Werner H., Beitner-Johnson D., Roberts C.T. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr. Rev. 1995, 16:143-163.
7. De Meyts P., Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat. Rev. Drug Discov. 2002, 1:769-783.
8. Hemkens L.G., Grouven U., Bender R., Gunster C., Gutschmidt S., Selke G.W., Sawicki P.T. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009, 52:1732-1744.
9. Jonasson J.M., Ljung R., Talback M., Haglund B., Gudbjornsdottir S., Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009, 52:1745-1754.
10. Colhoun H.M. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009, 52:1755-1765.
11. Pocock S.J., Smeeth L. Insulin glargine and malignancy: an unwarranted alarm. Lancet 2009, 374:511-513.
12. Smith U., Gale E.A. Does diabetes therapy influence the risk of cancer?. Diabetologia 2009, 52:1699-1708.
13. Sadick M.D., Intintoli A., Quarmby V., McCoy A., Canova-Davis E., Ling V. Kinase receptor activation (KIRA): a rapid and accurate alternative to end-point bioassays. J. Pharm. Biomed. Anal. 1999, 19:883-891.
14. Brugts M.P., Ranke M.B., Hofland L.J., van der Wansem K., Weber K., Frystyk J., Lamberts S.W., Janssen J.A. Normal values of circulating insulin-like growth factor-I bioactivity in the healthy population: comparison with five widely used IGF-I immunoassays. J. Clin. Endocrinol. Metab. 2008, 93:2539-2545.
15. Chen J.W., Ledet T., Orskov H., Jessen N., Lund S., Whittaker J., De Meyts P., Larsen M.B., Christiansen J.S., Frystyk J. A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum. Am. J. Physiol. Endocrinol. Metab. 2003, 284:E1149-E1155.
16. Kurtzhals P., Schaffer L., Sorensen A., Kristensen C., Jonassen I., Schmid C., Trub T. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000, 49:999-1005.
17. Boucher J., Tseng Y.H., Kahn C.R. Insulin and insulin-like growth factor-1 receptors act as ligand-specific amplitude modulators of a common pathway regulating gene transcription. J. Biol. Chem. 2010, 285:17235-17245.
18. Sciacca l., Cassarino M.F., Genua M., Pandini G., Le Moli R., Squatrito S., Vigneri R. Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia 2010, 53:1743-1753.
19. Shukla A., Grisouard J., Ehemann V., Hermani A., Enzmann H., Mayer D. Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr.-Relat. Cancer 2009, 16:429-441.
20. Eckardt K., May C., Koenen M., Eckel J. IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts. Diabetologia 2007, 50:2534-2543.
21. Pandini G., Frasca F., Mineo R., Sciacca L., Vigneri R., Belfiore A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J. Biol. Chem. 2002, 277:39684-39695.
22. Kuerzel G.U., Shukla U., Scholtz H.E., Pretorius S.G., Wessels D.H., Venter C., Potgieter M.A., Lang A.M., Koose T., Bernhardt E. Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr. Med. Res. Opin. 2003, 19:34-40.
23. Ekstrom K., Salemyr J., Zachrisson I., Carlsson-Skwirut C., Ortqvist E., Bang P. Normalization of the IGF-IGFBP axis by sustained nightly insulinization in type 1 diabetes. Diab. Care 2007, 30:1357-1363.
24. Murthy S.N., Sukhanov S., McGee J., Greco J.A., Chandra S., Delafontaine P., Kadowitz P.J., McNamara D.B., Fonseca V.A. Insulin glargine reduces carotid intimal hyperplasia after balloon catheter injury in Zucker fatty rats possibly by reduction in oxidative stress. Mol. Cell. Biochem. 2009, 330:1-8.
25. Slawik M., Schories M., Busse Grawitz A., Reincke M., Petersen K.G. Treatment with insulin glargine does not suppress serum IGF-1. Diabet. Med. 2006, 23:814-817.
26. Owens D.R., Bolli G.B. Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. Diab. Technol. Ther. 2008, 10:333-349.
27. Porcellati F., Rossetti P., Candeloro P., Lucidi P., Cioli P., Andreoli A.M., Ghigo E., Bolli G.B., Fanelli C.G. Short-term effects of the long-acting insulin analog detemir and human insulin on plasma levels of insulin-like growth factor-I and its binding proteins in humans. J. Clin. Endocrinol. Metab. 2009, 3017-3024.
28. Porcellati F., Rossetti P., Busciantella N.R., Marzotti S., Lucidi P., Luzio S., Owens D.R., Bolli G.B., Fanelli C.G. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diab. Care 2007, 30:2447-2452.
29. Sacco A., Morcavallo A., Pandini G., Vigneri R., Belfiore A. Differential signaling activation by insulin and insulin-like growth factors I and II upon binding to insulin receptor isoform A. Endocrinology 2009, 150:3594-3602.